New Insights in the Era of Clinical Biomarkers As Potential Predictors of Systemic Therapy-Induced Cardiotoxicity in Women with Breast Cancer: A Systematic Review

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2023 Jul 14

PMID 37444400

Authors

Alexia Alexandraki

Elisavet Papageorgiou

Marina Zacharia

Kalliopi Keramida

Andri Papakonstantinou

Carlo M Cipolla

Dorothea Tsekoura

Katerina Naka

Ketti Mazzocco

Davide Mauri

Manolis Tsiknakis

Georgios C Manikis

Kostas Marias

Yiola Marcou

Eleni Kakouri

Ifigenia Konstantinou

Maria Daniel

Myria Galazi

Effrosyni Kampouroglou

Domen Ribnikar

Cameron Brown

Georgia Karanasiou

Athos Antoniades

Dimitrios Fotiadis

Gerasimos Filippatos

Anastasia Constantinidou

Affiliations

Soon will be listed here.

Abstract

Aim: To provide an overview of existing and potentially novel biomarkers that possess a promising predictive value for the early and late onset of CTRCD in the clinical setting.

Methods: A systematic review of published studies searching for promising biomarkers for the prediction of CTRCD in patients with breast cancer was undertaken according to PRISMA guidelines. A search strategy was performed using PubMed, Google Scholar, and Scopus for the period 2013-2023. All subjects were >18 years old, diagnosed with breast cancer, and received breast cancer therapies.

Results: The most promising biomarkers that can be used for the development of an alternative risk cardiac stratification plan for the prediction and/or early detection of CTRCD in patients with breast cancer were identified.

Conclusions: We highlighted the new insights associated with the use of currently available biomarkers as a standard of care for the management of CTRCD and identified potentially novel clinical biomarkers that could be further investigated as promising predictors of CTRCD.

Citing Articles

Review of the clinical status of cardiotoxicity of HER-2 positive breast cancer targeted therapeutic drugs.

Zhang X, Yin Y, Yu Q, Chen X, Cheng Y Front Oncol. 2025; 14:1492203.

PMID: 39991185 PMC: 11842234. DOI: 10.3389/fonc.2024.1492203.

The Impact of Chemotherapy on Arterial Stiffness and Ventricular-Arterial Coupling in Women with Breast Cancer.

Kadoglou N, Dimopoulou A, Tsappa I, Pilavaki P, Constantinidou A Pharmaceuticals (Basel). 2024; 17(9).

PMID: 39338280 PMC: 11435293. DOI: 10.3390/ph17091115.

Serum Biomarkers to Dynamically Predict the Risk of Cardiovascular Events in Patients under Oncologic Therapy. A Multicenter Observational Study.

Provinciali N, Piccininno M, Siri G, Gennari A, Antonucci G, Ricci D Rev Cardiovasc Med. 2024; 25(7):256.

PMID: 39139415 PMC: 11317344. DOI: 10.31083/j.rcm2507256.

Kim H, Hong B, Kim S, Kang S, Park J Syst Rev. 2024; 13(1):167.

PMID: 38937811 PMC: 11212164. DOI: 10.1186/s13643-024-02588-z.

HER2/neu 655 polymorphism, trastuzumab-induced cardiotoxicity, and survival in HER2-positive breast cancer patients.

Blancas I, Linares-Rodriguez M, Martin-Bravo C, Gomez-Pena C, Rodriguez-Serrano F Clin Transl Oncol. 2024; 26(10):2531-2540.

PMID: 38771533 PMC: 11410839. DOI: 10.1007/s12094-024-03512-6.

References

Ryu H, Ahn S, Kim S, Kim J, Kim J, Ahn J . Comparison of metabolic changes after neoadjuvant endocrine and chemotherapy in ER-positive, HER2-negative breast cancer. Sci Rep. 2021; 11(1):10510. PMC: 8131718. DOI: 10.1038/s41598-021-89651-0. View

Dong Y, Wu Q, Hu C . Early Predictive Value of NT-proBNP Combined With Echocardiography in Anthracyclines Induced Cardiotoxicity. Front Surg. 2022; 9:898172. PMC: 9283786. DOI: 10.3389/fsurg.2022.898172. View

Nakano S, Takahashi M, Kimura F, Senoo T, Saeki T, Ueda S . Cardiac magnetic resonance imaging-based myocardial strain study for evaluation of cardiotoxicity in breast cancer patients treated with trastuzumab: A pilot study to evaluate the feasibility of the method. Cardiol J. 2016; 23(3):270-80. DOI: 10.5603/CJ.a2016.0023. View

Reuvekamp E, Bulten B, Nieuwenhuis A, Meekes M, de Haan A, Tol J . Does diastolic dysfunction precede systolic dysfunction in trastuzumab-induced cardiotoxicity? Assessment with multigated radionuclide angiography (MUGA). J Nucl Cardiol. 2015; 23(4):824-32. PMC: 4956716. DOI: 10.1007/s12350-015-0164-x. View

Zile M, Mehurg S, Arroyo J, Stroud R, DeSantis S, Spinale F . Relationship between the temporal profile of plasma microRNA and left ventricular remodeling in patients after myocardial infarction. Circ Cardiovasc Genet. 2011; 4(6):614-9. PMC: 3535326. DOI: 10.1161/CIRCGENETICS.111.959841. View

Marjot J, Kaier T, Martin E, Reji S, Copeland O, Iqbal M . Quantifying the Release of Biomarkers of Myocardial Necrosis from Cardiac Myocytes and Intact Myocardium. Clin Chem. 2017; 63(5):990-996. PMC: 6114147. DOI: 10.1373/clinchem.2016.264648. View

Ky B, Putt M, Sawaya H, French B, Januzzi Jr J, Sebag I . Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab. J Am Coll Cardiol. 2013; 63(8):809-16. PMC: 4286181. DOI: 10.1016/j.jacc.2013.10.061. View

Sardesai S, Sukumar J, Kassem M, Palettas M, Stephens J, Morgan E . Clinical impact of interruption in adjuvant Trastuzumab therapy in patients with operable HER-2 positive breast cancer. Cardiooncology. 2020; 6(1):26. PMC: 7643282. DOI: 10.1186/s40959-020-00081-9. View

Narayan H, Finkelman B, French B, Plappert T, Hyman D, Smith A . Detailed Echocardiographic Phenotyping in Breast Cancer Patients: Associations With Ejection Fraction Decline, Recovery, and Heart Failure Symptoms Over 3 Years of Follow-Up. Circulation. 2017; 135(15):1397-1412. PMC: 5388560. DOI: 10.1161/CIRCULATIONAHA.116.023463. View

10.

Dural M, Demir L, Babayigit E, Junushova B, Mert K, Ulus T . Fragmented QRS formation and its predictors in patients with breast cancer receiving anthracycline-based chemotherapy. J Electrocardiol. 2019; 54:5-9. DOI: 10.1016/j.jelectrocard.2019.02.003. View

11.

Schultz J, KAMINKER K . Myeloperoxidase of the leucocyte of normal human blood. I. Content and localization. Arch Biochem Biophys. 1962; 96:465-7. DOI: 10.1016/0003-9861(62)90321-1. View

12.

Wang H, Chen F, Tong J, Li Y, Cai J, Wang Y . Circulating microRNAs as novel biomarkers for dilated cardiomyopathy. Cardiol J. 2016; 24(1):65-73. DOI: 10.5603/CJ.a2016.0097. View

13.

Huang F, Brezden-Masley C, Chan K, Barfett J, Kirpalani A, Deva D . Evaluation of left atrial remodeling using cardiovascular magnetic resonance imaging in breast cancer patients treated with adjuvant trastuzumab. Eur Radiol. 2022; 32(6):4234-4242. DOI: 10.1007/s00330-021-08466-9. View

14.

Hooks M, Sandhu G, Maganti T, Chen K, Wang M, Cullen R . Incidental coronary calcium in cancer patients treated with anthracycline and/or trastuzumab. Eur J Prev Cardiol. 2022; 29(17):2200-2210. DOI: 10.1093/eurjpc/zwac185. View

15.

Dores H, Abecasis J, Correia M, Gandara F, Fonseca C, Azevedo J . Detection of early sub-clinical trastuzumab-induced cardiotoxicity in breast cancer patients. Arq Bras Cardiol. 2013; 100(4):328-32. View

16.

Cardinale D, Colombo A, Bacchiani G, Tedeschi I, Meroni C, Veglia F . Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation. 2015; 131(22):1981-8. DOI: 10.1161/CIRCULATIONAHA.114.013777. View

17.

Putt M, Hahn V, Januzzi J, Sawaya H, Sebag I, Plana J . Longitudinal Changes in Multiple Biomarkers Are Associated with Cardiotoxicity in Breast Cancer Patients Treated with Doxorubicin, Taxanes, and Trastuzumab. Clin Chem. 2015; 61(9):1164-72. PMC: 4667170. DOI: 10.1373/clinchem.2015.241232. View

18.

Ben Kridis W, Sghaier S, Charfeddine S, Toumi N, Daoud J, Kammoun S . A Prospective Study About Trastuzumab-induced Cardiotoxicity in HER2-positive Breast Cancer. Am J Clin Oncol. 2020; 43(7):510-516. DOI: 10.1097/COC.0000000000000699. View

19.

Coombes R, Kilburn L, Snowdon C, Paridaens R, Coleman R, Jones S . Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet. 2007; 369(9561):559-70. DOI: 10.1016/S0140-6736(07)60200-1. View

20.

Momen-Heravi F, Saha B, Kodys K, Catalano D, Satishchandran A, Szabo G . Increased number of circulating exosomes and their microRNA cargos are potential novel biomarkers in alcoholic hepatitis. J Transl Med. 2015; 13:261. PMC: 4533956. DOI: 10.1186/s12967-015-0623-9. View